Public Health & Policy >
Product Alert
FDA Blocks Sale of Supplements for Parkinson's and Alzheimer's
WASHINGTON -- The FDA filed a permanent injunction against two Minnesota companies that distributed amino acid products marketed as treatments for Parkinson's disease, Alzheimer's disease, and a number of other neurological disorders.
Sep 16, 2011
Consumer Group Urges Boxed Warning for PPIs
Citing research showing that withdrawal of proton pump inhibitors (PPIs) leads to severe rebound acid secretion -- potentially leaving patients permanently dependent on the drugs -- the consumer group Public Citizen has told the FDA that it should require black-box warnings with the drugs.
Aug 23, 2011
No Approval for Rifaximin in IBS
The FDA has indicated that, before the antibiotic drug rifaximin (Xifaxan) can be approved for treating irritable bowel syndrome, its manufacturer must provide data on how the agent should be used in retreating patients with recurrent symptoms, the company said.
Mar 08, 2011
FDA Warns GERD Drugs May Deplete Magnesium
WASHINGTON -- Use of prescription or over-the-counter proton pump inhibitors (PPI) for a year or longer may lead to low levels of circulating magnesium, which may increase the risk of leg spasms, arrhythmias, and seizures, according to an FDA warning.
Mar 02, 2011